Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 2/3 1Phase 1 1

Status

Completed 5Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 7OTHER 5NIH 1

Study Type

Interventional 7

Sponsor

Cancer Type

Endocrine 4Tumor-Agnostic 2NET 2Head & Neck 2Thoracic 1

Conditions

Neoplasms 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Neuroendocrine Tumors 2Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoid Tumor 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × fosbretabulin × Clear all
NCT02279602 2018-04-17

Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

Mateon Therapeutics

Phase 2 Completed
7 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02132468 2017-12-05

GI-NETorPNET

Mateon Therapeutics

Phase 2 Completed
18 enrolled 10 charts
EndocrineNET

Carcinoid Tumor, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00653939 2015-02-09

FALCON

Mateon Therapeutics

Phase 2 Completed
63 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00507429 2014-06-09

FACT

Mateon Therapeutics

Phase 2/3 Terminated
80 enrolled 10 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT01701349 2014-05-01

FACT2

Mateon Therapeutics

Phase 3 Withdrawn
EndocrineHead & Neck

Head and Neck Neoplasms, Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00113438 2011-11-01

Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors

Mateon Therapeutics

Phase 2 Completed
13 enrolled
Tumor-Agnostic

Neoplasms

NCT00395434 2011-10-31

Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

Mateon Therapeutics

Phase 1 Completed
20 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡